Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Change in Receivables (2019 - 2025)

AVITA Medical (RCEL) has disclosed Change in Receivables for 5 consecutive years, with -$81000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 94.56% year-over-year to -$81000.0, compared with a TTM value of $3.6 million through Dec 2025, up 187.65%, and an annual FY2025 reading of $3.6 million, up 187.65% over the prior year.
  • Change in Receivables was -$81000.0 for Q4 2025 at AVITA Medical, down from $2.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.3 million in Q3 2025 and bottomed at -$3.5 million in Q4 2023.
  • Average Change in Receivables over 4 years is -$255875.0, with a median of -$307500.0 recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 3378.3% in 2023, then soared 254.83% in 2025.
  • Year by year, Change in Receivables stood at $106000.0 in 2022, then plummeted by 3378.3% to -$3.5 million in 2023, then surged by 57.15% to -$1.5 million in 2024, then skyrocketed by 94.56% to -$81000.0 in 2025.
  • Business Quant data shows Change in Receivables for RCEL at -$81000.0 in Q4 2025, $2.3 million in Q3 2025, and $1.6 million in Q2 2025.